Skip to content

Tolerance and pharmacokinetics of PEG-INF-SA in healthly volunteers

Tolerance and pharmacokinetics of PEG-INF-SA in healthly volunteers:A Randomized, Single center, Dose-ranging, Open-Label study.

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-TNRC-11001393
Enrollment
Unknown
Registered
2011-06-20
Start date
2010-11-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis

Interventions

8:hypodermic

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Male subjects in the range of age from 18 to 40 years; 2. BMI within 19~24kg/m2, disparity of weirht body within ±10% for each group; 3. Subjects with normal findings as determined by baseline history, physical examination, vital signs (blood pressure, pulse rate, respiration rate and axillary temperature), Haemogram with ESR, Biochemistry, Infectious Disease Screening (HIV, Hepatitis B and Hepatitis C) and Urinalysis, ECG.,X-ray(chest); 4. Be in healthly, no history of cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological, metabolic, haematological, gastrointestinal, endocrine, immunological or psychiatric diseases; 5. Not be a smoker or an alcohol, and permitted no smoking and drink alcohol during the trial; 6. Willingness to follow the protocol requirement as evidenced by written, informed consent.

Exclusion criteria

Exclusion criteria: 1. With abnormal findings as determined by physical examination , vital signs and ECG. et al.; 2. History of chronic gastritis ,gastroenterocolitis or other medical conditions should affect the drug absorption, had known or suspected hypersensitive to the study drug; 3. Requiring medication for any ailment drugs in the previous 14 days; 4. Adminitrated study drug in the previous 60 days; 5. Participation in a clinical drug study or bioequivalence study 90 days prior to present study; 6. Blood donation 90 days prior to the commencement of the study; 7. History or presence of significant alcoholism or drug abuse in the past one year; 8. may be pregnancy during the trial, pregnancy and lactation woman; 9. History of any medical or surgical conditions in the previous 14 days.

Design outcomes

Primary

MeasureTime frame
tolerance;

Secondary

MeasureTime frame
drug metablism dynamic;

Countries

China

Contacts

Public ContactZhengli
lzheng2005618@yahoo.com.cn+86 18980601950

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026